FDA Approves Lembaz for Infantile Niemann-Pick Disease
The Food and Drug Administration approved Lembaz (adrabetadex) on Tuesday, November 17, 2026, Beren Therapeutics announced. The drug is approved to reduce the risk of death in adults and children weighing at least 7 kilograms whose Niemann-Pick disease type C symptoms began before age 6. The approval rests on a survival comparison against matched external controls, not a randomized trial, and the label carries a boxed warning for permanent hearing loss.
Edited and fact-checked by Stephen Sprague
About 475 children in the United States have the infantile-onset form of this disease, and the untreated mean age at death is about 5.6 years when symptoms start before age 2. Lembaz reaches treatment sites in early December, with hearing tests required before the first dose and on a set schedule after it.
A child with infantile-onset Niemann-Pick disease type C loses neurological function on a clock that families can measure in birthdays.
The Food and Drug Administration approved Lembaz, the brand name for adrabetadex, on Tuesday, November 17, 2026, Beren Therapeutics announced. The drug is approved to reduce the risk of death in adults and children who weigh at least 7 kilograms, about 15 pounds, and whose neurological symptoms began before age 6. It is given by intrathecal injection, delivered into the spinal fluid. Beren says the drug will be available at treatment sites nationwide in early December, and the company received a Priority Review Voucher with the approval.
Niemann-Pick disease type C is an autosomal recessive disorder. Variants in the NPC1 gene account for about 95 percent of cases, and variants in NPC2 account for the rest. Cholesterol gets trapped inside cells, including brain cells, and neurological damage accumulates. About 475 children in the United States have the infantile-onset form, roughly half of all people with the disease. The mean age at death is about 5.6 years when symptoms begin before age 2, and about 13.4 years when symptoms begin between ages 2 and 6.
Adrabetadex is a mixture of 2-hydroxypropyl-beta-cyclodextrin compounds. The mixture helps move cholesterol that is trapped inside brain cells to where cells can use it, which addresses the trafficking defect behind the disease rather than a downstream symptom. Elizabeth M. Berry-Kravis, a professor of pediatrics and neurological sciences at Rush University Medical Center and the lead investigator for the drug's expanded access program, said neurological function that is lost cannot be regained, so early diagnosis and prompt treatment matter.
The evidence boundary belongs in the open. The approval rests on an analysis of overall survival in patients treated in three clinical studies and an expanded access program, compared with matched external controls. The FDA determined that this comparison served as the adequate and well-controlled study supporting approval, and treatment was associated with a 55 percent reduction in the risk of death. That is a relative figure against historical controls, not a result from a randomized trial. The company's announcement did not report patient numbers, follow-up length, or confidence intervals for the approval analysis. An earlier analysis, presented in March 2026, compared 72 treated children with 119 matched controls and reported a 71 percent lower risk of death, with five-year survival of 84 percent against 42 percent. The two analyses are not the same dataset, and their numbers should not be blended.
The label's central risk is hearing. The drug carries a boxed warning for hearing impairment, including permanent hearing loss, and hearing loss from mild to profound has occurred in some patients whose hearing was normal before treatment. A baseline audiology evaluation, covering pure tone audiometry, speech recognition testing, and tympanometry, is required before the first dose. Hearing is retested one to two weeks after the first and second doses at each dosage level, then monthly once the dose is stable until three results in a row are stable, and every 12 months after that. The dose is not increased if hearing loss exceeds set limits, and it is not known whether continuing or lowering the dose changes the risk of further loss. Ataxia and fatigue can occur in the first days after a dose and have led to hospitalization. Adverse reactions reported in at least 25 percent of patients in a clinical trial were hearing impairment, ataxia, fatigue, vomiting, back pain, headache, fever, diarrhea, nausea, and cough.
Regulators have reversed themselves on this drug before. The FDA granted breakthrough therapy designation in 2016 under a previous sponsor, rescinded it after data from a 12-month phase 2b/3 trial, and granted the designation again in 2025. In 2024 the agency approved arimoclomol, used with miglustat, for neurological manifestations of the disease in adults and children aged 2 years and older. Lembaz is the first medicine approved to improve survival in the infantile-onset form, and its December arrival gives clinicians a treatment aimed at the youngest patients, the group with the shortest untreated timeline.
The conversation.
Loading comments…
A little more perspective.
Reading is free. Verified members can comment and reply for $2 a month.